Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Change in Receivables (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Change in Receivables for 11 consecutive years, with -$1600.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Receivables fell 101.16% year-over-year to -$1600.0, compared with a TTM value of -$151600.0 through Sep 2025, down 220.6%, and an annual FY2024 reading of $169100.0, up 5024.24% over the prior year.
  • Change in Receivables was -$1600.0 for Q3 2025 at BioRestorative Therapies, up from -$10000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $137600.0 in Q3 2024 and bottomed at -$163400.0 in Q1 2025.
  • Average Change in Receivables over 5 years is -$787.5, with a median of -$2300.0 recorded in 2021.
  • The sharpest move saw Change in Receivables surged 1000.0% in 2022, then tumbled 1140.76% in 2025.
  • Year by year, Change in Receivables stood at -$3000.0 in 2021, then plummeted by 866.67% to -$29000.0 in 2022, then soared by 31.03% to -$20000.0 in 2023, then skyrocketed by 217.0% to $23400.0 in 2024, then plummeted by 106.84% to -$1600.0 in 2025.
  • Business Quant data shows Change in Receivables for BRTX at -$1600.0 in Q3 2025, -$10000.0 in Q2 2025, and -$163400.0 in Q1 2025.